36 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

  • Sorrento Therapeutics, Inc. SRNE stock surged 35.0% to $2.16 during Monday's pre-market session. The market cap seems to be at $215.6 million. The most recent rating by JMP Securities, on October 07, is at Market Outperform, with a price target of $21.00.
  • Medicines Co, Inc. MDCO stock increased by 23.1% to $84.40. The market cap stands at $4.1 billion. The most recent rating by Baird, on November 25, is at Neutral, with a price target of $85.00.
  • Enochian BioSciences, Inc. ENOB shares surged 19.2% to $7.00. The market cap seems to be at $263.7 million.
  • Aquestive Therapeutics, Inc. AQST stock rose 18.2% to $7.60. The market value of their outstanding shares is at $96.1 million.
  • AnaptysBio, Inc. ANAB stock surged 15.2% to $13.85. The market cap stands at $1.0 billion. According to the most recent rating by Guggenheim, on November 08, the current rating is at Neutral.
  • Alnylam Pharmaceuticals, Inc. ALNY shares surged 7.6% to $115.00. The market value of their outstanding shares is at $9.6 billion. The most recent rating by Barclays, on November 21, is at Overweight, with a price target of $131.00.
  • Proteostasis Therapeutics, Inc. PTI shares surged 6.9% to $1.87. The market value of their outstanding shares is at $42.4 million.
  • ZIOPHARM Oncology, Inc. ZIOP stock rose 6.8% to $5.04. The market cap seems to be at $763.9 million.
  • Intercept Pharmaceuticals, Inc. ICPT stock moved upwards by 6.3% to $94.50. The market cap seems to be at $2.3 billion. The most recent rating by UBS, on November 12, is at Buy, with a price target of $135.00.
  • Myovant Sciences, Inc. MYOV shares moved upwards by 6.0% to $14.90. The market cap seems to be at $489.3 million. The most recent rating by Goldman Sachs, on August 28, is at Buy, with a price target of $20.00.
  • Arrowhead Pharmaceuticals, Inc. ARWR shares moved upwards by 6.0% to $52.16. The market value of their outstanding shares is at $2.6 billion. The most recent rating by Baird, on November 25, is at Outperform, with a price target of $70.00.
  • Clovis Oncology, Inc. CLVS stock increased by 5.3% to $9.12. The market cap stands at $173.7 million. The most recent rating by Evercore ISI Group, on November 19, is at In-Line, with a price target of $8.00.
  • Karuna Therapeutics, Inc. KRTX shares moved upwards by 4.7% to $89.00. The market value of their outstanding shares is at $325.9 million. The most recent rating by Goldman Sachs, on November 18, is at Buy, with a price target of $109.00.
  • Viveve Medical, Inc. VIVE stock increased by 4.4% to $0.96. The market cap stands at $6.8 million. The most recent rating by Stifel Nicolaus, on November 07, is at Hold, with a price target of $1.00.
  • BioCryst Pharmaceuticals, Inc. BCRX shares moved upwards by 4.0% to $2.34. The market cap seems to be at $220.8 million. According to the most recent rating by Bank of America, on November 15, the current rating is at Buy.
  • Canopy Growth, Inc. CGC shares increased by 3.8% to $19.10. The market cap seems to be at $6.9 billion. According to the most recent rating by Bank of America, on November 20, the current rating is at Buy.
  • Zealand Pharma, Inc. ZEAL stock rose 3.7% to $31.16. The market cap stands at $1.0 billion. According to the most recent rating by Jefferies, on November 19, the current rating is at Hold.
  • Organogenesis Holdings, Inc. ORGO shares increased by 3.7% to $4.90. The market cap seems to be at $664.1 million.
  • Intra-Cellular Therapies, Inc. ITCI stock rose 3.6% to $10.34. The market cap stands at $511.0 million.
  • Mylan, Inc. MYL shares increased by 3.5% to $17.95. The market cap stands at $9.8 billion. The most recent rating by Morgan Stanley, on November 07, is at Equal-Weight, with a price target of $18.00.
  • Diffusion Pharmaceuticals, Inc. DFFN shares increased by 3.2% to $0.32. The market value of their outstanding shares is at $3.9 million.
  • DelMar Pharmaceuticals, Inc. DMPI stock increased by 2.9% to $1.08. The market cap stands at $7.6 million. The most recent rating by Maxim Group, on September 06, is at Buy, with a price target of $2.00.
  • Teva Pharmaceutical Indus, Inc. TEVA stock surged 2.7% to $10.50. The market value of their outstanding shares is at $8.9 billion. According to the most recent rating by JP Morgan, on November 12, the current rating is at Neutral.
  • CRISPR Therapeutics, Inc. CRSP stock surged 2.6% to $63.85. The market cap stands at $2.7 billion. The most recent rating by Oppenheimer, on November 12, is at Outperform, with a price target of $65.00.
  • Ocugen, Inc. OCGN shares increased by 2.6% to $0.29. The market cap seems to be at $19.7 million.

 

Losers

  • CymaBay Therapeutics, Inc. CBAY stock plummeted 79.6% to $1.13 during Monday's pre-market session. The market cap seems to be at $308.4 million.
  • Adamis Pharmaceuticals, Inc. ADMP stock declined 52.4% to $0.60. The market value of their outstanding shares is at $49.7 million.
  • ASLAN Pharmaceuticals, Inc. ASLN shares fell 24.3% to $1.31. The market value of their outstanding shares is at $49.3 million. The most recent rating by H.C. Wainwright, on November 14, is at Buy, with a price target of $2.00.
  • InVivo Therapeutics Hldg, Inc. NVIV shares fell 12.1% to $0.14. The market cap stands at $4.3 million.
  • Phio Pharmaceuticals, Inc. PHIO stock declined 7.8% to $0.12. The market cap seems to be at $5.7 million.
  • Guardion Health Sciences, Inc. GHSI shares decreased by 5.7% to $0.20. The market value of their outstanding shares is at $20.3 million.
  • OrganiGram Holdings, Inc. OGI shares declined 4.9% to $2.51. The market cap seems to be at $536.7 million.
  • OpGen, Inc. OPGN stock plummeted 3.9% to $1.22. The market cap seems to be at $4.5 million.
  • Genfit, Inc. GNFT stock plummeted 3.8% to $14.65. The market value of their outstanding shares is at $552.9 million.
  • Eyegate Pharmaceuticals, Inc. EYEG stock plummeted 3.7% to $6.83. The market cap stands at $14.3 million.
  • VBI Vaccines, Inc. VBIV stock fell 3.2% to $0.62. The market cap seems to be at $104.2 million. The most recent rating by Raymond James, on November 14, is at Outperform, with a price target of $3.00.
  • Onconova Therapeutics, Inc. ONTX stock declined 2.9% to $0.15. The market cap stands at $4.3 million.

Posted In: Healthcare Stocks Pre-Market MoversTop GainersNewsMovers & ShakersPre-Market OutlookMarketsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.